Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Insulins | Original investigation

Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort

Authors: Roderick C. Slieker, Amber A. W. H. van der Heijden, Giel Nijpels, Petra J. M. Elders, Leen M. ’t Hart, Joline W. J. Beulens

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

Glycemic variation has been suggested to be a risk factor for diabetes-related complications. Previous studies did not address confounding of diabetes duration, number of visits and length of follow-up. Here, we characterize glycemic variability over time and whether its relation to diabetes-related complications and mortality is independent from diabetes- and follow-up duration.

Materials and methods

Individuals with type 2 diabetes (n = 6770) from the Hoorn Diabetes Care System cohort were included in this study. The coefficient of variation (CV) was calculated over 5-year sliding intervals. People divided in quintiles based on their CV. Cox proportional hazard models were used to investigate the role of glycemic CV as risk factor in diabetes-related complications and mortality.

Results

The coefficient of variation of glucose (FG-CV) increased with time, in contrast to HbA1c (HbA1c-CV). People with a high FG-CV were those with an early age of diabetes onset (ΔQ5–Q1 = − 2.39 years), a higher BMI (ΔQ5–Q1 = + 0.92 kg/m2), an unfavorable lipid profile, i.e. lower levels of HDL-C (ΔQ5–Q1 = − 0.06 mmol/mol) and higher triglycerides (ΔQ5–Q1 =+ 1.20 mmol/mol). People with the highest FG-CV in the first 5-year interval showed an increased risk of insulin initiation, retinopathy, macrovascular complications and mortality independent of mean glycemia, classical risk factors and medication use. For HbA1c, the associations were weaker and less consistent.

Conclusions

Individuals with a higher FG-CV have an unfavorable metabolic profile and have an increased risk of developing micro- and macrovascular complications and mortality. The association of HbA1c-CV with metabolic outcomes and complications was less consistent in comparison to FG-CV.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.CrossRef Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.CrossRef
2.
go back to reference Collaboration Emerging Risk Factors. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.CrossRef Collaboration Emerging Risk Factors. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.CrossRef
3.
go back to reference Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications. 2003;17(2):78–81.CrossRef Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications. 2003;17(2):78–81.CrossRef
4.
go back to reference Luk AO, Ma RC, Lau ES, Yang X, Lau WW, Yu LW, Chow FC, Chan JC, So WY. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metabolism Res Rev. 2013;29(5):384–90.CrossRef Luk AO, Ma RC, Lau ES, Yang X, Lau WW, Yu LW, Chow FC, Chan JC, So WY. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metabolism Res Rev. 2013;29(5):384–90.CrossRef
5.
go back to reference Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K, Hayashi T, Hanai K, Tanaka N, Ishii A, et al. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3(2):148–55.CrossRef Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K, Hayashi T, Hanai K, Tanaka N, Ishii A, et al. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3(2):148–55.CrossRef
6.
go back to reference Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–65.CrossRef Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359–65.CrossRef
7.
go back to reference Takao T, Matsuyama Y, Suka M, Yanagisawa H, Iwamoto Y. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000129.CrossRef Takao T, Matsuyama Y, Suka M, Yanagisawa H, Iwamoto Y. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000129.CrossRef
8.
go back to reference Bonke FC, Donnachie E, Schneider A, Mehring M. Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus. Diabetologia. 2016;59(2):286–93.CrossRef Bonke FC, Donnachie E, Schneider A, Mehring M. Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus. Diabetologia. 2016;59(2):286–93.CrossRef
9.
go back to reference Prentice JC, Pizer SD, Conlin PR. Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes. Diabetic Med. 2016;33(12):1640–8.CrossRef Prentice JC, Pizer SD, Conlin PR. Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes. Diabetic Med. 2016;33(12):1640–8.CrossRef
10.
go back to reference Wan EYF, Fung CSC, Wong CKH, Chin WY, Lam CLK. Association of hemoglobin A1c levels with cardiovascular disease and mortality in chinese patients with diabetes. J Am Coll Cardiol. 2016;67(4):456–8.CrossRef Wan EYF, Fung CSC, Wong CKH, Chin WY, Lam CLK. Association of hemoglobin A1c levels with cardiovascular disease and mortality in chinese patients with diabetes. J Am Coll Cardiol. 2016;67(4):456–8.CrossRef
11.
go back to reference Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48–57.CrossRef Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61(1):48–57.CrossRef
12.
go back to reference Muggeo M, Verlato G, Bonora E, Ciani F, Moghetti P, Eastman R, Crepaldi G, De Marco R. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia. 1995;38(6):672–9.CrossRef Muggeo M, Verlato G, Bonora E, Ciani F, Moghetti P, Eastman R, Crepaldi G, De Marco R. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia. 1995;38(6):672–9.CrossRef
13.
go back to reference Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, De Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus. Circulation. 1997;96(6):1750–4.CrossRef Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, De Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus. Circulation. 1997;96(6):1750–4.CrossRef
14.
go back to reference Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20:1885–93.CrossRef Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20:1885–93.CrossRef
15.
go back to reference Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013;126:e1–10.CrossRef Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013;126:e1–10.CrossRef
16.
go back to reference Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018;17(1):33.CrossRef Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018;17(1):33.CrossRef
17.
go back to reference Zhou JJ, Schwenke DC, Bahn G. Reaven PJDc: Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial. 2018;41(10):2187–94. Zhou JJ, Schwenke DC, Bahn G. Reaven PJDc: Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial. 2018;41(10):2187–94.
18.
go back to reference Tang X, Zhong J, Zhang H, Luo Y, Liu X, Peng L, Zhang Y, Qian X, Jiang B, Liu J, et al. Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):50.CrossRef Tang X, Zhong J, Zhang H, Luo Y, Liu X, Peng L, Zhang Y, Qian X, Jiang B, Liu J, et al. Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):50.CrossRef
19.
go back to reference Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2018;17(1):36.CrossRef Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2018;17(1):36.CrossRef
20.
go back to reference Noyes J, Soto-Pedre E, Donnelly L, Pearson E. Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes. Diabetic Med. 2017;35(2):262–9.CrossRef Noyes J, Soto-Pedre E, Donnelly L, Pearson E. Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes. Diabetic Med. 2017;35(2):262–9.CrossRef
21.
go back to reference Yang CP, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Li TC, Lin CC. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology. 2017;88(10):944–51.CrossRef Yang CP, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Li TC, Lin CC. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology. 2017;88(10):944–51.CrossRef
22.
go back to reference Low S, Lim SC, Yeoh LY, Liu YL, Liu JJ, Fun S, Su C, Zhang X, Subramaniam T, Sum CF. Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore. J Diabetes. 2016;9(10):908–19.CrossRef Low S, Lim SC, Yeoh LY, Liu YL, Liu JJ, Fun S, Su C, Zhang X, Subramaniam T, Sum CF. Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore. J Diabetes. 2016;9(10):908–19.CrossRef
23.
go back to reference van der Heijden AA, Rauh SP, Dekker JM, Beulens JW, Elders P, M‘t Hart L, Rutters F, Leeuwen N, Nijpels G. The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands. BMJ Open. 2017;7(5):e015599.CrossRef van der Heijden AA, Rauh SP, Dekker JM, Beulens JW, Elders P, M‘t Hart L, Rutters F, Leeuwen N, Nijpels G. The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands. BMJ Open. 2017;7(5):e015599.CrossRef
24.
go back to reference Rutten G, De Grauw W, Nijpels G, Houweling S, Van de Laar F, Bilo H, Holleman F, Burgers J, Wiersma T, Janssen P. NHG-Guideline Diabetes mellitus type 2 (third revision). Huisarts Wetenschap. 2013;56(10):512–25. Rutten G, De Grauw W, Nijpels G, Houweling S, Van de Laar F, Bilo H, Holleman F, Burgers J, Wiersma T, Janssen P. NHG-Guideline Diabetes mellitus type 2 (third revision). Huisarts Wetenschap. 2013;56(10):512–25.
25.
go back to reference Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–8.CrossRef Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–8.CrossRef
26.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef
27.
28.
go back to reference Disease Kidney. Improving Global Outcomes (KDIGO) CKD-MBD Work Group: kDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130. Disease Kidney. Improving Global Outcomes (KDIGO) CKD-MBD Work Group: kDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.
29.
go back to reference Mast R, Jansen AD, Walraven I, Rauh SP, van der Heijden AA, Heine RJ, Elders PJ, Dekker JM, Nijpels G, Hugtenburg JG. Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study. Eur J Endocrinol. 2016;174(5):563–71.CrossRef Mast R, Jansen AD, Walraven I, Rauh SP, van der Heijden AA, Heine RJ, Elders PJ, Dekker JM, Nijpels G, Hugtenburg JG. Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study. Eur J Endocrinol. 2016;174(5):563–71.CrossRef
30.
go back to reference Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia. 2018;61(1):66–74.CrossRef Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia. 2018;61(1):66–74.CrossRef
31.
go back to reference Zoppini G, Verlato G, Targher G, Casati S, Gusson E, Biasi V, Perrone F, Bonora E, Muggeo M. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutrition Metab Cardiovasc Dis. 2009;19(5):334–9.CrossRef Zoppini G, Verlato G, Targher G, Casati S, Gusson E, Biasi V, Perrone F, Bonora E, Muggeo M. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutrition Metab Cardiovasc Dis. 2009;19(5):334–9.CrossRef
32.
go back to reference Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38:2354–69.CrossRef Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38:2354–69.CrossRef
33.
go back to reference Lin CC, Yang CP, Li CI, Liu CS, Chen CC, Lin WY, Hwang KL, Yang SY, Li TC. Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study. BMC Med. 2014;12:165.CrossRef Lin CC, Yang CP, Li CI, Liu CS, Chen CC, Lin WY, Hwang KL, Yang SY, Li TC. Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study. BMC Med. 2014;12:165.CrossRef
34.
go back to reference Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2013;12:98.CrossRef Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2013;12:98.CrossRef
35.
go back to reference Sugawara A, Kawai K, Motohashi S, Saito K, Kodama S, Yachi Y, Hirasawa R, Shimano H, Yamazaki K, Sone H. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: tsukuba Kawai Diabetes Registry 2. Diabetologia. 2012;55(8):2128–31.CrossRef Sugawara A, Kawai K, Motohashi S, Saito K, Kodama S, Yachi Y, Hirasawa R, Shimano H, Yamazaki K, Sone H. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: tsukuba Kawai Diabetes Registry 2. Diabetologia. 2012;55(8):2128–31.CrossRef
36.
go back to reference Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Lee YS, Shin SJ, Tai TY. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia. 2012;55(12):3163–72.CrossRef Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Lee YS, Shin SJ, Tai TY. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia. 2012;55(12):3163–72.CrossRef
37.
go back to reference Cheng D, Fei Y, Liu Y, Li J, Xue Q, Wang X. HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis. PLoS ONE. 2014;9:e115509.CrossRef Cheng D, Fei Y, Liu Y, Li J, Xue Q, Wang X. HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis. PLoS ONE. 2014;9:e115509.CrossRef
38.
go back to reference Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. J Diabetes Compl. 2014;28(2):185–90.CrossRef Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. J Diabetes Compl. 2014;28(2):185–90.CrossRef
Metadata
Title
Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort
Authors
Roderick C. Slieker
Amber A. W. H. van der Heijden
Giel Nijpels
Petra J. M. Elders
Leen M. ’t Hart
Joline W. J. Beulens
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0975-1

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.